This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Vivos Therapeutics, Inc. (VVOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vivos Therapeutics, Inc. (VVOS) delivered earnings and revenue surprises of -17.65% and 3.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 12.50% and 3.97%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -7.50% and 175%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 12.99% and 94.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 11.76% and 2.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -50.57% and 40.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Baudax Bio, Inc. (BXRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of 17.32% and 61.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -4% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Vivos (VVOS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.